Secondary Logo

Journal Logo

Clinical Science Aspects

S1PR1-Associated Molecular Signature Predicts Survival in Patients with Sepsis

Feng, Anlin; Rice, Amanda D.; Zhang, Yao∗,†; Kelly, Gabriel T.; Zhou, Tong; Wang, Ting

Author Information
doi: 10.1097/SHK.0000000000001376



Although clinical medicine has advanced significantly in past decades, sepsis remains a significant cause of death in hospitalized patients around the world. Roughly 1 million cases result in an estimated 200,000 deaths every year in the United States (1). Sepsis is a systemic syndrome triggered by infections, including bacterial infections. During infection, the host immune system interacts with pathogens and produces downstream inflammatory and anti-inflammatory responses leading to a global response which could result in multi-organ dysfunction and mortality (approximately 13% in sepsis-3 (2) (previous term is severe sepsis) patients (3) and 40% in septic shock patients) (4).

Fast and appropriate treatment is the foundation for therapy of sepsis. However, differentiating sepsis-3 patients from sepsis cases may be a problem. Currently, no biomarkers are available for sepsis which allow for a rapid and dependable prognosis for sepsis patients (5). Due to the complicity of the syndrome, a prognostic biomarker of mortality or disease development is not well established.

Sphingosine-1-phosphate (S1P) is a bioactive plasma-membrane sphingolipid which plays an essential role in multiple critical signaling pathways including immunomodulation (6). S1P production has been found to be well correlated with the susceptibility and severity of many inflammatory diseases such as asthma (7), autoimmunity (8), and sepsis (9, 10). S1P signaling occurs via interactions with a family of G-protein-coupled S1P receptors (S1PR1–S1PR5). These receptors perform vital but distinct roles in a range of cellular processes variably characterized by their receptor-specific downstream signaling pathways. S1PR1, the first identified S1P receptor and the most well characterized, is the receptor most predominantly expressed in the immune system. S1PR1 regulates multiple biological processes including cellular proliferation (11), maintenance of human embryonic stem cells (12), migration of various types of immune cells including lymphocytes, regulatory T cells, and dendritic cells (13–15), and cytokine secretion (16). Interestingly, blood possesses the highest S1P concentration compared with all other body tissues (17), and the circulating plasma S1P maintains vascular integrity against endogenous and exogenous endothelial integrity disruptors including growth factors, pathogens, and toxins (18).

S1P-S1PR1 axis is considered to play a vital role in the development of sepsis. There are multiple reports demonstrating the molecular mechanism of S1PR1 in the pathogenesis of sepsis (9). One recent report suggested the S1PR1 agonist SEW2871 is effective in improving the microcirculation and protecting against kidney injury in a murine model of sepsis (19).

During infection and inflammation, the activation of S1PR1 by S1P is a negative regulator, reversing the increase in pulmonary vascular permeability induced by lipopolysaccharide (20). The ligation of S1P to S1PR1 maintains the homeostatic barrier within the vascular system. Therefore, the S1P–S1PR1 axis restores the integrity of the vascular barrier and stabilizes blood vessels (21). Consequently, it is likely that the activation of vascular S1PR1 reduces the severe complications in sepsis and is suggested to improve the survival rate of sepsis patients.

This study aimed to understand the involvement of S1PR1 in sepsis and identify S1PR1-related genes that also regulate sepsis survival. First, we analyzed two Gene Expression Omnibus (GEO) datasets from whole blood samples of sepsis patients and built the first S1PR1-related gene signature, which we show can also predict the outcomes of sepsis patients. By analyzing gene expression data, we found a 62-gene and 16-gene S1PR1-associated molecular signature that can even predict survival of sepsis patients. These results suggest that peripheral blood gene expression data can be used to predict the survival of sepsis patients.


GEO datasets selection

We carried out a systematic search in the GEO database for clinical studies of sepsis. Search items included whole blood samples from sepsis patients and microarray datasets with survival data. Several studies were identified after exclusion of studies in animals, RNA-seq datasets, or non-whole blood samples. GEO: GSE54514 was designated as the discovery cohort and GEO: GSE33118 as the validation cohort. In GSE54514, daily whole blood samples were detected for up to 5 days for sepsis non-survivors (n = 9) and sepsis survivors (n = 26) (22). The blood samples of GSE33118 included sepsis non-survivors (n = 10) and sepsis survivors (n = 10) (Table 1, Supplementary Table 1, and 2, For GSE54514, first-day blood samples were collected within the first 24 h of intensive care unit (ICU) admission. For GSE33118, blood samples were taken within 12 h of diagnosis.

Table 1:
Demographics of discovery and validation cohort.

Sepsis was diagnosis as documented bacterial infection in addition to the presence of at least two of the following clinical criteria: fever (temperature > 100.4°F (38°C) or hypothermia (temperature < 96.8°F (36°C)); heart rate > 90 beats/min; tachypnea (> 20 breaths/min or PaCO2 < 4.3 kPa); white blood cell count > 12,000 cells/μL, or < 4,000 cells/μL, or with > 10% band forms (22).

Sepsis survival-related genes and S1PR1-related genes

The limma package ( was used to identify differentially expressed genes (DEGs) between non-survivors and survivors in the discovery cohort and was referred to as sepsis survival-related genes. We conducted Pearson correlation test to identify all the S1PR1-coexpressed genes in the discovery cohort as our S1PR1-related genes in method 1. For method 2, S1PR1-related genes were identified from the STRING database ( which was based on protein interactions and signaling pathways.

Expression score and risk score

We allocated expression (for the whole genome) and risk score (for sepsis survival-related genes) for each patient using a linear combination of expression values of genes in the signature. The formula corresponding to expression and risk score are: 

Here, n is the count of genes included in gene signature in each dataset, Wi represents the weight value of the ith gene (see in Table 2), ei represents the expression level of the ith gene, and μi and si are the corresponding mean and standard deviation value for the ith gene among whole samples.

Table 2:
Clinical characteristics of sepsis patients in discovery and validation cohort.

Statistical analyses

All the statistical calculations were performed by the R 3.5.2. Principal component analysis (PCA, by scatterplot3d package) and receiver operating characteristic (ROC) curves (pROC package) were used in this study to verify the differentiating power of this S1PR1-related molecular signatures (SMS) on sepsis survival status. False discovery rate (FDR) < 0.05 was considered statistically significant.


S1PR1-correlated genes significantly overlap with sepsis survival-related genes

Two GEO datasets (GSE54514 and GSE33118) with 55 sepsis patients were included in our study, and Table 2 showed the clinical characteristics of study population. We utilized two methods to identify the S1PR1-related genes (Fig. 1). The first method is to define the genes that co-expressed with S1PR1 as S1PR1-related genes. In total, we found 557 genes (Pearson r > 0.4 and FDR < 0.05) that were co-expressed with S1PR1 in the discovery dataset. Both positive and negative co-expression genes were included in our study. To determine the DEGs in the whole blood transcriptome that correlated with the survival outcome of sepsis patients, we analyzed the gene expression data from nine non-survivors and 26 survivors in the discovery cohort. One thousand seventy-eight up-regulated and 1,134 down-regulated genes in sepsis (fold change > 1.2 and FDR < 5%) were identified as survival-related genes.

Fig. 1:
Schematic of workflow of discovery of gene signature.

We used the DAVID Bioinformatics Resources 6.8 ( (23, 24) to identify enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways among the S1PR1-related and sepsis survival-related genes. Our analyses revealed several immune-pathways were significantly associated with S1PR1 co-expressed genes (adjusted P value < 0.05). The top KEGG pathways were significantly associated with several pathways such as B cell receptor signaling pathways, cytotoxicity, and cell adhesion molecules (Fig. 2A). Furthermore, we noticed that several innate immune or infection pathways are associated with the DEGs between sepsis survivors and non-survivors (Fig. 2B).

Fig. 2:
62-gene signature in sepsis patients.

Among these sepsis survival-related genes, 62 genes overlapped with the S1PR1-correlated genes (Table 3, Fig. 2C, cumulative hypergeometric test: P < 0.05), confirming a pivotal role for S1PR1-signaling in sepsis pathogenesis. Here, several innate and adaptive immune pathways were also found as enriched among the 62 genes (Fig. 2D). However, these 62 proteins did not have strong protein interactions with each other (Supplementary Figure 1,

Table 3:
S1PR1-related gene signatures.

In method 2, we utilized the STRING database ( to generate a list of all S1PR1-associated genes based on signaling pathways, experimental data, co-expression data, and public text collections (25). Two hundred thirty-three genes were found as having high confidence (> 0.7) interaction score with S1PR1 (Supplementary Table 3, Several immune system pathways (TNF signaling pathway, Toll-like receptor signaling pathway, and T, B cell receptor signaling pathway, etc.) and vascular system pathways (EGFR tyrosine kinase inhibitor resistance, and VEGF signaling pathway) were enriched among the pathway-based S1PR1-related genes (Fig. 3A). Most of the signaling pathways were consistent with the S1PR1-related pathways mentioned in the literature (26).

Fig. 3:
16-gene signature in sepsis patients.

Sixteen genes overlapped with the sepsis survival-related genes and S1PR1-related genes in method 2 (Table 3, Fig. 3B). KEGG analysis (Fig. 3C) identifies several strongly enriched pathways, including Chemokine signaling pathway, B-cell receptor signaling pathway, VEGF signaling pathway, etc. Next, we wanted to visualize the interactions within the 16 genes with protein–protein interaction (PPI) network. To generate the PPI network, PPI data was acquired from the STRING database. The clustering analysis was also performed in the PPI network by MCODE module in Cytoscape 3.6.1 (Fig. 3D). We obtained two clusters of proteins with more dense interactions than average. One group is related to Staphylococcus aureus infection, the other group is related to chemokine signaling pathway, T, B cell receptor signaling pathway, VEGF signaling pathway, etc.

S1PR1 gene signature predicts clinical outcome in both discovery and validated cohorts

When arranged for hierarchical clustering, the expression heatmaps of the genes in both the 62-gene and 16-gene signatures were able to differentiate non-survivors from survivors (Figs. 2E and 3E), which suggests the significant power of discriminating survival patients from non-survival patients. To compare the overall survival (OS) of patients with different gene signature expressions, we grouped the patients based on the total gene expression of the 62 or 16 genes in the discovery cohort. Higher or lower than median value was used to differentiate high or low expression groups. The results (Figs. 2F and 3F) showed that the low expression group for both two sets of genes had more inferior OS than the high expression group.

To make the prediction feasible with one unique “survival prognosis score,” a scoring system representing a linear combination of the 62-gene expression and 16-gene expression (Table 3) values with a weight value was constructed to allocate each patient with a score to measure the possibility of risk. A higher risk score represented a worse clinical outcome. Our results focused on both the discovery and validation cohort. The result is in line with our expectations; either the 62-gene or 16-gene risk scores from non-survivors were significantly higher than those of survivors in the discovery cohort, while, more importantly, it was repeatedly observed in the independent validation cohort (Figs. 4A and 5A). Therefore, both of our S1PR1-based gene signatures had the statistical power to predict clinical out come in sepsis. We named our two gene signatures SMS.

Fig. 4:
The 62-gene signature-based sepsis risk score differentiates non-survivors from survivors in both the discovery and validation cohort.

Fig. 5:
The 16-gene signature-based sepsis risk score differentiates non-survivors from survivors in both the discovery and validation cohort.

Classification power of the gene signature

The ROC curve was utilized to visualize how well the gene signatures can distinguish between non-survivors and survivors. For the 62-gene signature, the areas under the curve (AUC) for the ROC curve were 1 and 0.86 for the discovery and validation cohorts, respectively (Fig. 4B). For the 16-gene signature, the AUC values were 0.98 and 0.83 for the discovery and validation cohorts, respectively (Fig. 5B). We investigated the classification performance of the SMS signature in the discovery and validation datasets. Principal component analyses (Figs. 6 and 7) showed that the SMS thoroughly distinguished non-survival patients from survival patients in the discovery cohort, while exhibiting minimal overlaps in the validation cohort.

Fig. 6:
3D PCA plot of the 62-gene signature for the discovery cohort (A) and validation cohort (B).

Fig. 7:
3D PCA plot of the 16-gene signature for the discovery cohort (A) and validation cohort (B).

A bioinformatics study by Venet et al. (27) shows that most gene signatures randomly selected from the human genome with the same genes size sometimes were better than published gene signatures. To confirm whether this issue existed in our study, we further applied resampling tests a total of 10,000 permeations to generate the expression score or risk score for each patient to generate the corresponding AUC value for each random gene signature. Each independent permeation randomly selected 62 or 16 genes of random sizes from the whole genome. It is of interest that the SMS gene signature had higher power on the classification of sepsis survival than randomly generated genes with the same gene count (better than 95% random gene signatures in the whole genome) (Figs. 4C and 5C). This quality control data confirmed the significance of the prognostic power of SMS while demonstrating that it was not population specific.

We next compared the performance of gene signatures 1 and 2 (Table 4). The sepsis risk prediction accuracy is almost the same according to the P and AUC value. However, signature 2 has better internal protein interactions (PPI P value) than gene signature 1.

Table 4:
Statistical comparison between gene signatures 1 and 2.


Sepsis is the primary cause of admission in the ICU (3). The pathology of sepsis and its associated systemic inflammatory response syndrome, which can lead to multi-organ dysfunction and even death, is still poorly understood. Lipoproteins, such as S1PR1, are increasingly identified as essential mediators influencing the progression and disease outcome of sepsis (28, 29). Serum S1P levels are radically decreased and are inversely related to disease severity in sepsis (29, 30). S1P binds to S1PR1 in immune or endothelial cells, leading to release of cytokines (31) and regulation of vascular integrity (20), suggesting that S1PR1 could be used as a therapeutic molecule in sepsis. However, S1PR1-related genes that also can be used for predicting survival in sepsis are still missing. Linking the gap between in vitro or in vivo model results and clinical diseases is necessary for medical researchers. Identifying gene expression signatures can disclose a variety of clinical and biological characteristics of patients’ samples. In this study, we analyze GEO datasets containing whole-genome gene expression data from both non-survival and survival patients with sepsis. Our results have several contributions as follows: Confirmed the correlation of S1PR1-dependent signaling in sepsis survival with bioinformatics tools; SMS is an “independent” prognostic marker of sepsis survival; Potential to move forward to a second-generation biomarker for sepsis prognosis and therapy decisions, thus fulfilling the need for “precision medicine.”

Biomarkers for sepsis can be used for diagnosis, risk assessment, and survival prediction. One hundred seventy-eight biomarkers have been verified for evaluating of sepsis (32). However, no single biomarker such as C-reactive protein (33) and Procalcitonin (34) have adequate sensitivity or specificity for diagnosis and prognosis to be regularly used in clinical practice to date. Compared with the single-gene biomarker, multigene biomarkers and corresponding sepsis risk scoring methods showed higher AUC values in ROC curves (35). More and more researches begin to focus on using Genome-wide expression analysis to better predict the clinical outcome of sepsis. Genome-wide expression analysis offers of examining the entire transcriptome of a tissue, and assessing gene expression changes without any bias. Our multi-gene biomarkers have been derived from SP1R1 signaling networks showed high prediction power, which was shown in both a discovery and validation cohort, has the potential to be extended to clinical trial in the future.

Compared with other sepsis biomarkers, our gene signatures have several advantages: the two gene signatures, especially the 16 gene signature, have a strong relationship with signaling pathways and protein interactions. Our S1PR1 gene signatures both reflect the status of the immune and vascular systems during infections which was regulated by S1PR1, so this explains why our sets of genes are the pivotal factor for predicting the risk of sepsis patients; the resampling tests which compared random gene signatures with our gene signatures has confirmed the significance of the prognostic power of our gene signatures; we only included the sepsis samples from whole blood sample and microarray datasets, which made our results more consistent and comparable. Whole blood samples and microarray datasets meet our needs as a rapid and dependable prognosis for sepsis patients.

To generate validated and accurate bioinformatic information, we performed our studies with multiple layers of quality control. First, one independent validation cohort was used. Second, the AUC values from ROC curves and PCA plots showed that these S1PR1-derived SMS are powerful tools to provide an essential prognostic method to distinguish sepsis patients with high risk from sepsis patients with low risk. Lastly, gene signatures selected may not have a better outcome predictor than random signatures from whole genome or sepsis survival-related genes (27). So, we used resampling tests to reveal whether the 62-gene or 16-gene signature has more power prediction than random gene signatures. Our results show that our gene signatures have superior predictive power than that of most gene sets randomly chosen from whole genome or sepsis survival-related genes.

In this study, we showed that S1PR1-related gene signatures are capable of distinguishing patients with higher risk from other sepsis patients. However, our work in S1PR1-related gene signatures was only based on bioinformatics methods. We only included sepsis datasets with whole blood samples in this study, so the potential power of our gene signature needs to be verified in additional datasets which contained peripheral blood mononuclear cell samples or studies from larger multicenter. Additionally, we can test our gene signature in the devastating complication of sepsis such as acute respiratory distress syndrome which have similar underlying mechanisms with sepsis.


In conclusion, we obtained gene signatures containing 62 and 16 protein-coding genes, which we demonstrated to be reproducible predictors of clinical outcome in patients with sepsis. Thus, our results could have potential value in clinical evaluations and disease monitoring in patients with sepsis.


The authors thank their tutors and lab members for providing valuable help.


1. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity 40:463–475, 2014.
2. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810, 2016.
3. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41:1167–1174, 2013.
4. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370:1412–1421, 2014.
5. Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence 5:154–160, 2014.
6. Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 75:1893–1900, 2008.
7. Sun X, Ma SF, Wade MS, Flores C, Pino-Yanes M, Moitra J, Ober C, Kittles R, Husain AN, Ford JG, et al. Functional variants of the sphingosine-1-phosphate receptor 1 gene associate with asthma susceptibility. J Allergy Clin Immunol 126:241–249, 2010. 249.e1–3.
8. Garris CS, Wu L, Acharya S, Arac A, Blaho VA, Huang Y, Moon BS, Axtell RC, Ho PP, Steinberg GK, et al. Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol 14:1166–1172, 2013.
9. Gräler MH. The role of sphingosine 1-phosphate in immunity and sepsis. Am J Clin Exp Immunol 1:90–100, 2012.
10. Winkler MS, Nierhaus A, Poppe A, Greiwe G, Graler MH, Daum G. Sphingosine-1-phosphate: a potential biomarker and therapeutic target for endothelial dysfunction and sepsis? Shock 47:666–672, 2017.
11. Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 114:155–167, 1991.
12. Pébay A, Wong RCB, Pitson SM, Wolvetang EJ, Peh GS-L, Filipczyk A, Koh KLL, Tellis I, Nguyen LTV, Pera MF. Essential roles of sphingosine-1-phosphate and platelet-derived growth factor in the maintenance of human embryonic stem cells. Stem Cells 23:1541–1548, 2005.
13. Lan YY, De Creus A, Colvin BL, Abe M, Brinkmann V, Coates PTH, Thomson AW. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 5:2649–2659, 2005.
14. Chi H. Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci 32:16–24, 2011.
15. Priceman SJ, Shen S, Wang L, Deng J, Yue C, Kujawski M, Yu H. S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. Cell Rep 6:992–999, 2014.
16. Teijaro JR, Studer S, Leaf N, Kiosses WB, Nguyen N, Matsuki K, Negishi H, Taniguchi T, Oldstone MBA, Rosen H. S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-( autoamplification. Proc Natl Acad Sci U S A 113:1351–1356, 2016.
17. Murata N, Sato K, Kon J, Tomura H, Okajima F. Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. Anal Biochem 282:115–120, 2000.
18. Yanagida K, Hla T. Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient. Annu Rev Physiol 79:67–91, 2017.
19. Wang Z, Sims CR, Patil NK, Gokden N, Mayeux PR. Pharmacologic targeting of sphingosine-1-phosphate receptor 1 improves the renal microcirculation during sepsis in the mouse. J Pharmacol Exp Ther 352:61–66, 2015.
20. Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, Saba J, Vogel SM, Malik AB, Mehta D. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res 103:1164–1172, 2008.
21. Jung B, Obinata H, Galvani S, Mendelson K, Ding BS, Skoura A, Kinzel B, Brinkmann V, Rafii S, Evans T, et al. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell 23:600–610, 2012.
22. Parnell GP, Tang BM, Nalos M, Armstrong NJ, Huang SJ, Booth DR, McLean AS. Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions. Shock 40:166–174, 2013.
23. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane H, Lempicki RA. DAVID: database for annotation. Visualization, and integrated discovery. Genome Biol 4:P3, 2003.
24. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1–13, 2009.
25. Snel B, Lehmann G, Bork P, Huynen MA. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res 28:3442–3444, 2000.
26. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22:50–60, 2012.
27. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7:e1002240, 2011.
28. Murch O, Collin M, Hinds CJ, Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 33:13–24, 2007.
29. Coldewey SM, Benetti E, Collino M, Pfeilschifter J, Sponholz C, Bauer M, Huwiler A, Thiemermann C. Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. Sci Rep 6:27594, 2016.
30. Winkler MS, Nierhaus A, Holzmann M, Mudersbach E, Bauer A, Robbe L, Zahrte C, Geffken M, Peine S, Schwedhelm E, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit Care 19:372, 2015.
31. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, Martinborough E, Peach R, Oldstone MBA, Rosen H. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:980–991, 2011.
32. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 14:R15, 2010.
33. Miguel-Bayarri V, Casanoves-Laparra EB, Pallás-Beneyto L, Sancho-Chinesta S, Martín-Osorio LF, Tormo-Calandín C, Bautista-Rentero D. Prognostic value of the biomarkers procalcitonin, interleukin-6 and C-reactive protein in severe sepsis. Med Intensiva 36:556–562, 2012.
34. Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care Lond Engl 17:R291, 2013.
35. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, Moretti E, Nguyen HB, Gunnerson KJ, Milzman D, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 37:96–104, 2009.

Microarray; S1PR1; sepsis; SMS; AUC; area under the curve; DEGs; differentially expressed genes; GEO; gene expression omnibus; OS; overall survival; PPI; protein-protein interaction; ROC; receiver operating characteristic; S1PR1; sphingosine-1-phosphate and its receptor S1P receptor 1; SMS; S1PR1-related molecular signatures

Supplemental Digital Content

Copyright © 2019 by the Shock Society